These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 16854066

  • 1. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ.
    J Med Chem; 2006 Jul 27; 49(15):4606-15. PubMed ID: 16854066
    [Abstract] [Full Text] [Related]

  • 2. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
    Lee K, Ryu JS, Jin Y, Kim W, Kaur N, Chung SJ, Jeon YJ, Park JT, Bang JS, Lee HS, Kim TY, Lee JJ, Hong YS.
    Org Biomol Chem; 2008 Jan 21; 6(2):340-8. PubMed ID: 18175003
    [Abstract] [Full Text] [Related]

  • 4. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ, Wang Z, MacMillan KS, Zhou Y, Carreras CW, Mueller T, Myles DC, Liu Y.
    J Med Chem; 2009 May 28; 52(10):3265-73. PubMed ID: 19405528
    [Abstract] [Full Text] [Related]

  • 5. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 01; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 8. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC, Mukund SR, Coulstock ET, Sengerovà B, Shaw J, McLaughlin SH, Jackson SE.
    J Mol Biol; 2007 Sep 14; 372(2):287-97. PubMed ID: 17662999
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.
    Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC.
    Bioorg Med Chem; 2004 Oct 15; 12(20):5317-29. PubMed ID: 15388159
    [Abstract] [Full Text] [Related]

  • 10. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ, Gaisser S, Challis IR, Carletti I, Wilkinson B, Gregory M, Prodromou C, Roe SM, Pearl LH, Boyd SM, Zhang MQ.
    J Med Chem; 2008 May 08; 51(9):2853-7. PubMed ID: 18357975
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z, Jia L, Wang J, Wu X, Hao H, Xu H, Wu Y, Shi G, Lu C, Shen Y.
    Eur J Med Chem; 2014 Oct 06; 85():359-70. PubMed ID: 25105924
    [Abstract] [Full Text] [Related]

  • 12. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.
    J Med Chem; 2007 Jun 14; 50(12):2767-78. PubMed ID: 17488003
    [Abstract] [Full Text] [Related]

  • 13. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L.
    Clin Cancer Res; 2003 Oct 15; 9(13):4961-71. PubMed ID: 14581371
    [Abstract] [Full Text] [Related]

  • 14. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 15. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P.
    Oncogene; 2000 Aug 24; 19(36):4125-33. PubMed ID: 10962573
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 17. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ.
    Nature; 2003 Sep 25; 425(6956):407-10. PubMed ID: 14508491
    [Abstract] [Full Text] [Related]

  • 18. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y, Ding J.
    Ai Zheng; 2004 Aug 25; 23(8):968-74. PubMed ID: 15301726
    [Abstract] [Full Text] [Related]

  • 19. Heat shock protein 90: inhibitors in clinical trials.
    Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC.
    J Med Chem; 2010 Jan 14; 53(1):3-17. PubMed ID: 20055425
    [No Abstract] [Full Text] [Related]

  • 20. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
    Maroney AC, Marugan JJ, Mezzasalma TM, Barnakov AN, Garrabrant TA, Weaner LE, Jones WJ, Barnakova LA, Koblish HK, Todd MJ, Masucci JA, Deckman IC, Galemmo RA, Johnson DL.
    Biochemistry; 2006 May 02; 45(17):5678-85. PubMed ID: 16634649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.